Information Provided By: 
Fly News Breaks for March 7, 2018
IPXL
Mar 7, 2018 | 07:33 EDT
SunTrust analyst John Boris initiated Impax with a Buy rating and a price target of $24. Boris says the NewCo of Impax and Amneal combines to form the 5th largest global generics company poised for long term expansion, with estimated sales and EBITDA annualized growth of over 49% and 95% respectively. The analyst also points to company's "robust" free cash flow generation while it pays down its debt.
News For IPXL From the Last 2 Days
There are no results for your query IPXL
